{
  "id": 3008028,
  "title": "Gilead: European Commission Approves Trodelvy Plus Keytruda In PD-L1-positive Metastatic TNBC",
  "url": "https://urgent.news/2026/08/24/gilead-european-commission-approves-trodelvy-plus-keytruda-in-pd-l1",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-08-24T10:51:52.000Z",
  "source": {
    "name": "Nasdaq Markets",
    "slug": "nasdaq-markets",
    "url": "https://www.nasdaq.com/articles/gilead-european-commission-approves-trodelvy-plus-keytruda-pd-l1-positive-metastatic-tnbc"
  },
  "original_language": "en",
  "account": null,
  "summary": "(RTTNews) - Gilead Sciences (GILD) announced the European Commission has granted marketing authorization for Trodelvy in combination with Keytruda for the treatment of adult patients with unresectable, locally advanced or metastatic triple-negative breast cancer who have not rec",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 2,
    "also_reported_by": [
      {
        "outlet": "Investing.com",
        "title": "European Commission approves Trodelvy-Keytruda combo for TNBC",
        "url": "https://urgent.news/2026/08/24/european-commission-approves-trodelvy-keytruda-combo-for-tnbc",
        "published": "2026-08-24T10:36:34.000Z"
      }
    ]
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}